Review

Reprogramming of Energy Metabolism in Response to Radiotherapy in Head and Neck Squamous Cell Carcinoma

Alfredo Cruz-Gregorio 1*, Imelda Martínez-Ramírez 1, José Pedraza-Chaverri 2,* and Marcela Lizano 1,3,*

1 Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de CancerologÍa, México/Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México. San Fernando No. 22, Col. Sección XVI, Tlalpan, Ciudad de México 14080, México; cruzgalfredo@gmail.com (A.C.-G); immara02@yahoo.com.mx (I.M.-R)
2 Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México 04510, México
3 Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México 04510, México
* Correspondence: pedraza@unam.mx (J.P.-C.); lizano@unam.mx (M.L.); Tel.: +51-5622-3878 (J.P.-C); +51-5628-0400 (ext. 31035) (M.L)

Received: 20 December 2018; Accepted: 1 February 2019; Published: 5 February 2019

Abstract: Head and neck cancer (HNC) is the sixth cause of cancer-related death worldwide. Head and neck squamous cells carcinoma (HNSCC) is the most frequent subtype of HNC. The development of HNSCC is associated to alcohol consumption, smoking or infection by high-risk human Papillomavirus (HR-HPV). Although the incidence of cancers associated with alcohol and tobacco has diminished, HNSCC associated with HR-HPV has significantly increased in recent years. However, HPV-positive HNSCC responds well to treatment, which includes surgery followed by radiation or chemoradiation therapy. Radiation therapy (RT) is based on ionizing radiation (IR) changing cell physiology. IR can directly interact with deoxyribonucleic acid (DNA) or produce reactive oxygen and nitrogen species (RONS), provoking DNA damage. When DNA damage is not repaired, programmed cell death (apoptosis and/or autophagy) is induced. However, cancer cells can acquire resistance to IR avoiding cell death, where reprogramming of energy metabolism has a critical role and is intimately connected with hypoxia, mitochondrial physiology, oxidative stress (OS) and autophagy. This review is focused on the reprogramming of energy metabolism in response to RT in HPV-positive and HPV-negative HNSCC, showing their differences in cellular metabolism management and the probable direction of treatments for each subtype of HNSCC.

Keywords: HNSCC; HR-HPV; radiotherapy; reprogramming of energy metabolism; metabolic therapy; oxidative stress

1. Introduction

Head and neck cancer (HNC) represents the sixth cause of cancer-related death worldwide, affecting mainly the male sex [1]. Head and neck squamous cell carcinoma (HNSCC) is the most abundant subtype of HNC. These malignancies are associated to alcohol consumption and smoking; however, infection by high-risk human Papillomavirus (HR-HPV) has been implicated in the development of HNSCC. The proportion of HNSCC associated with HR-HPV has increased from 16.3% during 1984 to 1989 to 71.7% in the period of 2000–04 in the United States [2]. However, it has
been shown that the HNSCC cases positive to HPV have a better response to radiation treatment in comparison with HPV-negative HNSCC cases [3].

Persistent infection with HR-HPV is the main risk factor for HPV-positive HNSCC, where HPV-16 is the most prevalent type [4]. The development of cancer is associated to the constant expression of E6 and E7 HPV oncoproteins, which modulate numerous cellular signaling pathways, resulting in immortalization and transformation [5]. A key feature in cancer development is the viral genome integration into host genome, which commonly leads to the breaking of the viral E2 open reading frame, promoting the overexpression of E6 and E7 oncogenes [6]. The process of integration is associated to different facts that induce deoxyribonucleic acid (DNA) breaks; for example: rupture of chromosomal fragile sites [7], decrease in DNA repair machinery activity [8], replication stress [9] or oxidative stress (OS) [10].

Radiotherapy (RT) used for tumour elimination is mainly based on ionizing radiation (IR). IR consists in electromagnetic radiation such as γ-rays or χ-rays, which carries enough energy to liberate electrons from atoms or molecules, ionizing them [11]. IR can interact with DNA provoking DNA double-strand breaks (DSBs), single-strand breaks (SSBs) or can induce the production of reactive oxygen and nitrogen species (RONS), such as superoxide anion (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), hydroxyl radical (OH$^-$) and peroxynitrite (ONOO$^-$), among others [12]. These RONS are neutralized by different cellular antioxidant enzymes such as: superoxide dismutases (SODs), catalase (CAT), glutathione peroxidase (GPx), peroxiredoxin (Prxs), and thioredoxin reductase (TrxR); and non-enzymatic antioxidants including: glutathione (GSH) and vitamins A, C, or E (Figure 1). However, if RONS overpass the antioxidant effects, a cellular oxidant condition appears called OS, where cellular molecules such as DNA, proteins, or lipids are oxidized and damaged, leading to cell death [13]. Thus, IR induces cancer cell death directly and indirectly through DNA damage and OS. Nevertheless, after cancer cells are exposed to IR, numerous cell processes are activated, where resistance to IR can be induced, avoiding cell death. For example, cancer cells can increase the DNA damage response (DDR) rate, which involves the activation of different signaling pathways associated to the DSB repairing, decreasing the DNA damage induced by IR. One of those signaling pathways is the epidermal growth factor receptor (EGFR)-phosphatidylinositol 3-kinase (PI3K)/protein kinasa B (Akt) pathway, where DNA-dependent protein kinase (DNA-PK), a molecule required for DNA repair via non-homologous end joining (NHEJ), is activated [14].

IR activates the ataxia telangiectasia mutated (ATM)-checkpoint kinase 2 (Chk2) pathway, which detects DSB and activates p53, breast cancer (BRCA) protein, p95/NBS1 and CtlP, inducing cell cycle arrest and DSB repair [15]. IR also activates the ATR-Chk1 pathway [16], which senses DNA SSBs, which in turn activates p38 mitogen-activated protein kinases (MAPKs), promoting DNA repair through the activation of the χ-ray repair cross-complementing protein 1 (XRCC1) [17]. Moreover, IR induces the overexpression of sirtuin 1 (SIRT1), which then activates the apurinic/apyrimidinic endodeoxyribonuclease (APEX1), stimulating the DNA base excision repair (BER) pathway [18,19].

Additionally, IR deregulates cell adhesion molecules such as E-cadherin, N-cadherin, Wnt1-inducible signaling pathway protein-1 (WISP1), vimentin, twist-related protein 1 (TWIST), SNAIL1, fibronectin and vitronectin (VTN), which favour the epithelial mesenchymal transition (EMT) [20–23]. It is noteworthy that when DDR and EMT are induced in the tumour cells, the tumour microenvironment (TME) is also affected, playing a critical role in the acquisition of radioresistance. For example, IR induces damage and death of the endothelial cells that surround tumour cells, which increases cytokines and chemokines levels, initiating an inflammatory response [24]. Chronic inflammation induces fibrosis in the endothelial cells, characterized by the repair and remodelling of the tissue, where molecules such as integrins, transforming growth factor-β (TGFβ) and connective tissue growth factor (CTGF) are secreted, which provoke tumour cell survival [25].

The cancer-associated fibroblasts (CAF) are key cells in the TME, that when exposed to IR, release growth factors such as TGF-β, extracellular matrix (ECM) modulators and cytokines, favouring tumour cell growth. IR reduces vascular diameter, activating hypoxia-inducible factor 1α (HIF1α) and
vascular endothelial growth factor (VEGF), provoking the release of chemokine (C-X-C motif) ligand 12 (CXCL12), which altogether protect tumour cells from cellular stress and death. Therefore, IR affects the vasculature, immune system and stroma, which could induce hypoxia and radioresistance [26].

A critical cellular condition in the induction of radioresistance is the reprogramming of energy metabolism, which is a cellular condition favoured in cancer cells, where energy production in the form of ATP is mainly obtained through glycolysis (Warburg effect) instead of oxidative phosphorylation (OXPHOS), even in presence of oxygen and with mitochondrial optimal function [27]. This hallmark of cancer can be presented in different fashions among the different cancers, where in certain conditions cells use either glycolysis or OXPHOS to obtain energy. Nevertheless, the use of glycolysis or OXPHOS could change in response to IR. Therefore, this review is focused on the mechanisms involved in the reprogramming of energy metabolism during radiotherapy response in HPV-negative and HPV-positive HNSCC.

2. Genetic Alterations in HPV-Positive and HPV-Negative HNSCC

HPV-positive and -negative HNSCC present differences in etiology, molecular properties, epidemiology, genetic alterations (mutations and copy number aberrations) and in their response to treatment [28–30]. Some studies report that the mutation rate is higher in HPV-negative HNSCC in relation to HPV-positive cases [31,32]. In contrast, other studies show that the mutation rate is not significantly different between both groups, although the genomic aberration profiles are different [33,34]. For instance, HPV-negative HNSCC has a higher number of mutations in TP53, CDKN2A, MLL2, CUL3, NSD1, FGFR1, DDR2, EGFR, FGFR2/3, EPHA2, PIK3CA and NOTCH genes; while HPV-positive cases present mutations in genes such as DDX3X, FGFR2/3, PIK3CA, KRAS and MLL2/3 [33]. Interestingly, some mutations can coincide in both groups; however, the mutation rate in a set of genes is different in relation to the HPV status. For example, PIK3CA, DDR2 or NF-kB genes are significantly mutated in HPV-positive HNSCC, which are associated to the activation of glutamine and lipid metabolisms and mitochondrial respiration, key processes involved in the development of these tumours [35–37]. On the contrary, mutations found in HPV-negative HNSCC cases inactivate the function of tumour suppressors such as p53, favouring glycolysis; since when p53 is functionally active, it induces the inhibition of glycolysis mainly through the activation of the protein TP53-induced glycolysis and apoptosis regulator (TIGAR) and the repression of glucose transporter 1 and 4 (GLUT1 and GLUT4) [38]. Therefore, the loss of p53 probably contributes to the induction of the Warburg effect instead of OXPHOS in order to obtain energy in the form of ATP.

3. Radiosensitivity in HPV-Positive HNSCC

Alcohol consumption, smoking, and infection with HR-HPV are the main etiological factors associated to HNSCC [39,40]. Regardless of the etiologic factor, the treatment regimen for HNSCC is usually the same; nevertheless, HNSCC can be divided into two subgroups: HPV-positive and HPV-negative, having mutually exclusive features. HPV-positive HNSCC patients have a better prognosis, whose HNSCC tumours present lower p53 mutation rate and have a better response to IR than HPV-negative tumours [41].

In HPV-positive HNSCC, the residual p53, when it is not degraded by the HPV E6 oncoprotein, can be activated after IR, inducing cell cycle arrest and apoptosis [42]. It has also been demonstrated that the capacity of repair of DSB is impaired in HPV-positive HNSCC [43].
Figure 1. Redox state in irradiated HNSCC cells and the effect of HPV oncoproteins. HNSCC cells regulate oxidative stress induced by IR through the overexpression of Nrf2, which in turn activates genes such as catalase, superoxide dismutase (SOD2) and glutathione peroxidase (GPx), associated to antioxidant processes. On the other hand, the HR-HPV E6 protein induce OS, which decreases the GSH/GSSG rate, the levels of catalase and its activity [44]. E6* decreases SOD2 and GPx, provoking OS and consequently, DNA damage [45]. E6/E7 activate Nrf2, inducing OS and DNA damage [46]. Therefore, altogether, HPV oncoproteins could sensitize HNSCC cells to radiation therapy.

Previously, we showed that HPV16 and HPV18 early-expressed proteins E1, E2, E6 and E7, differentially modulate the cellular redox state [44]. The co-expression of E1/E2 decreased the relation of reduced vs oxidized GSH (GSH/glutathione disulfide [GSSG]) and also decreased the expression and activity of SOD1/2, increasing RONS levels, OS and DSB. It was also demonstrated that the E6 oncoprotein increased RONS levels, OS and DSB, reducing the rate of GSH/GSSG, catalase expression and its activity, while E7 decreased RONS production due to the increase in GSH and catalase levels and its activity [44]. On the other hand, it has been shown that E6*, an isoform of E6, decreased the levels of SOD2 and GPx proteins, inducing reactive oxygen species (ROS) production (Figure 1) [45]. Those works suggest that the presence of different levels of E6 and E7 proteins in particular cellular contexts could influence the different phenotypes of HPV-positive tumours. Therefore, OS induced by HR-HPV could synergize with the OS induced by IR, eliciting the radiosensitivity observed in HPV-positive HNSCC.

OS associated to ROS deregulation is harmful and favours cell death. For example, H$_2$O$_2$ (even O$_2^-$) reacts in the Fenton reaction to induce OH$^-$ production, which in turn induces DNA damage; if DNA is not repaired, cellular death via apoptosis is induced [47]. However, ROS are also necessary for cell proliferation. Such is the case of H$_2$O$_2$ that can oxidize cysteine inducing disulphide bonds in proteins such as growth factor receptors (GFR), which are then activated promoting cellular proliferation [48]. The concentration of ROS establishes either cell death or proliferation. Therefore, ROS balance is essential to maintain cellular homeostasis. Cancer cells can augment the DDR rate...
and even control elevated ROS concentrations by inducing the enzymatic antioxidant expression (SOD and CAT, among others) or by increasing levels of non-enzymatic antioxidants, such as GSH or nicotinamide adenine dinucleotide phosphate (NADPH). NADPH indirectly regulates ROS production, since NADPH is a cofactor of different antioxidant enzymes such as the thioredoxin reductase (TrxR) and glutathione reductase (GR), which in turn are associated to the reduction of peroxiredoxin (Prx) or GSSG to GSH. NADPH is over-produced during the reprogramming of energy metabolism, mainly through the pentose phosphate pathway (PPP), activated in the Warburg effect [49]. Therefore, HPV-negative HNSCC could cope with high levels of ROS induced by IR due to the activation of their antioxidant battery and PPP activation via the Warburg effect, which does not occur in HPV-positive HNSCC [44,45,50].

4. Nuclear Factor (Erythoid-Derived 2)-Like 2 (Nrf2) Induces Radioresistance in HNSCC

Cells produce a myriad of RONS and free radicals, which are defined as chemical species that exist independently and contain one or more unpaired electrons. Those molecules are produced either by endogenous processes such as electron leakage in the electron transport chain (ETC) of the mitochondria or exogenous processes (smoking, ozone exposure, hyperoxia, IR or heavy metal ions), which can damage DNA, lipids, proteins or carbohydrates causing cellular dysfunction and/or cell death [51]. Cells have developed antioxidant systems that regulate these oxidant species; however, if such systems are overcome, OS is induced [52]. Therefore, efficient mechanisms for the protection against oxidant metabolites are necessary to maintain cell viability. These include both, antioxidant enzymes and non-enzymatic systems that use chelators or scavengers of ROS [53]. For example, vitamin C (ascorbic acid), vitamin E (α-tocopherol), GSH, carotenoids (β-carotene) and ubiquinone are all low-molecular weight antioxidants that neutralize free radicals, preventing cell damage from OS [54,55]. On the other hand, enzymes with antioxidant activity also prevent cell damage caused by ROS. Such is the case of SODs (Cu-Zn SOD and Mn-SOD), Prxs, GPx, glutathione S-transferases (GST), CAT and heme oxygenase-1 (HO-1), which are activated in response to OS. SODs, Prxs, GPx, GST, CAT and HO-1 are regulated by the transcription factor Nrf2 [56,57]. Nrf2 is one of the main transcription factors involved in the antioxidant response, since under OS, it dissociates from the Keap1/Cul3 complex avoiding its degradation via proteasome, which in turn stabilizes Nrf2, which is now able to translocate to the nucleus [57]. In the nucleus Nrf2 binds to the antioxidant response elements (ARE) of genes encoding antioxidant enzymes, as well as phase II detoxification enzymes of rapid induction and activation [56]. The main genes activated by Nrf2 include antioxidant enzymes such as HO-1 [58–60], NAD(P) H:quinone oxidoreductase 1 (NQO1) [60,61] and Prx1 [62,63]. It has been shown that in prostate cancer Nrf2 activation protects against OS, inducing radioresistance [64]. On the other hand, loss of Nrf2 activation is associated with radiosensitivity in lung and pancreatic cancers [61,65]. It has been demonstrated that in HPV-negative HNSCC cells, activation of Nrf2 is also associated with resistance to treatment [66] and conversely, its deactivation induces radiosensitivity. This Nrf2 activation in HNSCC is also associated to the upregulation of HO-1, NQO1 and GST, which are effective antioxidants (Figure 1) [67].

On the contrary, it has been shown that the transfection of HPV E6/E7 oncogenes in HNSCC cells induce ROS production via NADPH oxidase 2 (Nox2), another source of ROS generation that does not involves electron leakage in the mitochondrial ETC, which increases radiosensitivity in HPV-positive HNSCC (Figure 1) [46].

5. Radioresistance and Glucose Metabolism in HNSCC

The reprogramming of energy metabolism, considered as a hallmark of cancer, is a dynamic process which is induced to ensure a stable generation of energy and biomass, where glucose is the major molecule that supplies both [68,69]. In differentiated cells, glucose is metabolized through glycolysis and OXPHOS, where glycolysis, carried out in the cytosol, metabolizes glucose to pyruvate, which in turn is transported into the mitochondria and degraded to acetyl-CoA, continuing its
metabolism in the tricarboxylic acid (TCA) cycle, producing flavin adenine dinucleotide (FADH$_2$), guanosine triphosphate (GTP), coenzyme A (Co-A-SH) and nicotinamide adenine dinucleotide (NADH). NADH functions as an electron donor promoting OXPHOS. Therefore, the major amount of energy in the form of ATP is obtained in the mitochondria, since in OXPHOS, 34 ATP molecules are obtained in comparison with 2 ATP obtained by in glycolysis in the cytosol. However, in cancer cells glucose is converted to lactate instead of acetyl-CoA from pyruvate, even when mitochondria are functional in the presence of an adequate oxygen supply and OXPHOS can be carried out. The process where glycolysis is favoured instead of OXPHOS, yet with regular O$_2$ concentrations in cancer cells, is called Warburg effect [27]. This process is related to elevated levels of lactate and pyruvate, due to the overexpression and activation of glycolytic regulatory enzymes, such as hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase (PK) [70–72]. Moreover, ras, src and myc oncogenes induce the overexpression of glucose transporters (GLUT1 and 3), providing glucose and maintaining the Warburg effect [73,74].

The Warburg effect gives a metabolic advantage to cancer cells in order to produce fast energy and biomass, as well as glycolytic intermediates, which can be used in other processes, such as the PPP, lipid synthesis or nucleotide production [27]. Moreover, this metabolic rewiring causes resistance to radiotherapy in cancer cells. Kunkel et al. [75] demonstrated that GLUT-1 is overexpressed in radioresistant HNSCC tumours; however, if this transporter is inhibited, HNSCC are sensitized to IR [76]. The increase of GLUT-1 was associated with an increase of glucose uptake in radioresistant HNSCC cells, where glucose metabolism is favoured in comparison with glutamine metabolism [77]. HPV-negative HNSCC cells promote glycolysis, where an overexpression of HK2 and PDK1 enzymes occurs [78]. It was demonstrated that when an inhibitor of PDK1 was used in HPV-negative HNSCC, the cells became radiosensitized, which supports the association of glucose metabolism and HNSCC radioresistance [78]. In contrast, HPV-positive HNSCC cells express low levels of HK2 and PDK1 enzymes (Figure 2).

**Figure 2.** Metabolic reprogramming in HNSCC in response to IR. Activation of glycolysis and HIF1 in HPV-negative HNSCC cells induce radioresistance, in comparison to radiosensitive HPV-positive HNSCC cells, where OXPHOS is activated increasing ROS production and OS. In the presences of HPV, COX augments, activating the electron transport chain. Glucose transporter (GLUT), hexokinase (HK), phosphoglucone isomerase (PGI) phosphofructokinase (PFK), hypoxia-inducible factor (HIF), vascular endothelial growth factor (VEFG), pyruvate dehydrogenase kinase (PDK), pyruvate dehydrogenase (PDH), pyruvate dehydrogenase complex (PDC), cytochrome c oxidase (COX), tricarboxylic acid (TCA) cycle, cytochrome (cit), apoptosis protease-activating factor (Apaf), caspase (Cas), lactate dehydrogenase (LDH). The double arrow represents overexpression.
6. Role of Mitochondria in Irradiated HNSCC

Mitochondria are closely related to tumorigenesis, where multiple processes are undertaken such as OXPHOS, fatty acid oxidation (β-oxidation) or aspects involving mitochondrial fission, fusion and biogenesis, as well as cell signaling and cell death [79]. Therefore, the participation of mitochondria in cancer is critical, permitting cancer cells to adapt to cellular metabolic requirements. Moreover, the mitochondria have a critical role in cancer treatments including radiotherapy [80]. Li et al. [81] showed that in HNSCC cells, growth differentiation factor 15 (GDF15) promotes radioresistance, activating mitochondrial membrane potential and decreasing ROS through the SMAD1 pathway. Although radiotherapy induces ROS, cancer cells can decrease ROS production through the increase of antioxidants such as Mn-SOD, causing radioresistance [82]. As a counterpart, it has been shown that in a nasopharyngeal carcinoma cell model the silencing of Mn-SOD gene induces radiosensitivity [83].

It has been demonstrated that HPV-positive HNSCC cells use mitochondrial respiration instead of glucose metabolism, since high levels of cytochrome c oxidase (COX), the key enzyme in the mitochondrial respiratory pathway, are produced, with a significative increase in the COX/HKII ratio [78]. In comparison, in HPV-negative HNSCC the mitochondrial OXPHOS is decreased, favouring the glycolytic process (Figure 2) [77].

Mitochondria also function as a checkpoint for proliferation, since they sense the cell suitability before this demanding metabolic process starts. Furthermore, mitochondria can release cytochrome c, inducing apoptosis; however, BCL2 and BCL2 like 1 (BCL2L1), that are antiapoptotic proteins, are overexpressed in HNSCC, which avoids cytochrome c release [84], inducing radioresistance (Figure 2) [84–87].

7. Hypoxia and ROS in Response to Radiotherapy in HNSCC

Oxygen is the key molecule in the respiration process, because it receives the electrons, producing water in the last step of OXPHOS [88]. Nevertheless, cells can be deprived of a constant feed of oxygen, in a process known as hypoxia, favouring the Warburg effect and angiogenesis [89,90]. Hypoxia activates different transcription factors such as the members of the HIF family: HIF1, HIF2 and HIF3, which in turn induce the expression of the vascular endothelial growth factor (VEFG), a key transcription factor that favours angiogenesis and facilitates the assimilation of oxygen and nutrients [91]. HIF1 activation is associated to radioresistance, since it activates different genes associated to cell cycle arrest such as MYC or CDC25A [92,93] and glycolysis through the upregulation of pyruvate dehydrogenase kinase 2 (PDK2), decreasing pyruvate dehydrogenase (PDH) activity. In consequence, pyruvate levels augment avoiding its processing to acetyl-CoA [94]. It has been shown that HIF1 is overexpressed in HPV-negative HNSCC cells, but it is downregulated in HPV-positive HNC (Figure 2) [78].

8. Lipid Metabolism in HNSCC Radioresistance

Cancer cells can reprogram lipid metabolism, including the increase in the uptake of exogenous lipids or the constant synthesis of monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs), in order to satisfy the high demand of biomass and energy [95]. Moreover, long-chain polyunsaturated fatty acids (LC-PUFAs), such as arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are related to a wide variety of biological functions, since LC-PUFAs are substrates of eicosanoids that work as signal molecules or transcription regulators [96]. PUFAs are also major components of membrane phospholipids, affecting their permeability, transport functions, ion channel formation and fluidity, which depends on the number and type of these fatty acids [97]. A decrease in these lipids favouring a membrane rich in saturated phospholipids protects from lipid peroxidation and decrease antitumor drug uptake, increasing their resistance to treatment [98]. However, cancer cells can interchange saturated for polyunsaturated fatty acids to induce motility and metastasis [95]. Through both sources, uptake and synthesis can induce lipid accumulation, which is
stored in lipid droplets (LDs); so, in cancer cells, the LDs increase is considered as a hallmark of cancer aggressiveness, inducing resistance to chemotherapy [99].

Cells exposed to IR spread energy through water radiolysis inducing oxidants such as O$_2^*$, H$_2$O$_2$, HO*, carbon, oxygen, sulphur, and nitrogen radicals. These molecules oxidize fatty acids, which then induce lipid peroxidation chain reactions, altering the structure and function of the cell. For example, lipid peroxidation produces mutagenic and carcinogenic by-products such as trans-4-hydroxy-2-nonenal (4HNE) and malondialdehyde (MDA) [13]. It was shown that MDA directly forms adducts with the pyrimidines and purines bases of DNA, generating mutations and DNA damage, that induce cell death when not repaired [47]. IR also induces changes in the plasma and organelles membranes, showing new activity and distribution of the membrane microdomains, which are clusters of fatty acids with ceramide and cholesterol. These microdomains are organizers of the intracellular transport and signaling events, which could trigger different cancer mechanisms such as migration or cell proliferation [100]. Although the IR dose and the composition of microdomains have a critical role in the induction of cell death or cell proliferation, the mechanism is not completely understood, needing further investigation.

Mims et al. [77] showed that HPV-negative HNSCC radioresistant cells prefer to use glycolysis instead of OXPHOS to produce energy. This cancer hallmark could be detrimental in the inner part of tumours where the microenvironment is hypoxic, since glucose uptake and glycolysis significantly decrease [101]. However, these cells have increased fatty acid biosynthesis via fatty acid synthase (FAS) overexpression to produce ATP [68]. This advantage in HPV-negative HNSCC radioresistant cells could cover the energy requirement of the cancer cells for continued proliferation [77,101]. Therefore, lipid metabolism is also a critical process to be considered in the treatment of HNSCC associated to radiotherapy.

The peroxidation of PUFAs in the cytoplasmic and mitochondrial membranes can induce programmed cell death (apoptosis and/or autophagy). Thus, after exposure to radiation, cells need to cope to the process of peroxidation by reprogramming the metabolism of lipids and/or by inducing a battery of antioxidants that protect from lipid peroxidation [13]. These include SODs, catalase, peroxidases and vitamin E, among others. Therefore, oxidative effects in the cell due to radiation exposure are decreased by the increase in antioxidant levels and through the changes in metabolic pathways. However, these protective mechanisms could not be sufficient to deal with OS, inducing apoptosis and/or autophagy.

9. Autophagy in HNSCC Radioresistance

Autophagy is a programmed cell death process that involves cellular recycling using the degradation of cellular constituents in lysosomes. Autophagy also maintains homeostasis providing cell cytoprotection, which involves remodeling, recovery, and renewal of the cells, removing cell damage and hazardous aggregates of proteins, as well as whole organelles such as mitochondria, or intracellular pathogens [102]. It has been shown that nuclear tumour zones have deficient vascularization, inducing nutrient and oxygen deprivation and metabolic stress. In these conditions, autophagy is triggered promoting the metabolism of cellular proteins, carbohydrates and lipids in order to provide nutrients, which avoids metabolic stress and in consequence maintains cell survival and tumour growth [103]. In these tumour zones, the mammalian target of rapamycin (mTOR) is deactivated, which induces the autophagy process; conversely, autophagy deactivation is due to the reactivation of mTOR, so there exists an inversely proportional relationship between autophagy and mTOR [104]. Therefore, autophagy has a significant role in feeding carbon metabolism, including carbohydrates, lipids, and nucleotides. These molecules that proceed from autophagy can enter and reinforce glycolysis, TCA cycle activity or PPP pathway [105]. In this way, cancer cells have an incredible adaptation to nutrient deprivation rewiring carbon metabolism through the autophagy process.
It has been proposed that autophagy, but not apoptosis, is the main contributor to radioresistance, eliminating cell damage and contributing to carbon metabolism [106]. Autophagy is activated via p63, which is overexpressed in HNSCC radioresistance [107,108]. Regarding HPV, in cells that express E7, autophagy is increased providing molecules to maintain carbon metabolism [109]; but in contrast, E6 expression activates mTOR, the principal deactivator of autophagy [110]. Since in cancer, both E6 and E7 oncoproteins are present, the ratio of expression of E6/E7 could determine the induction of autophagy. However, to the best of our knowledge HPV-positive HNSCC autophagy induced by IR has not yet investigated.

Although HPV-negative or -positive HNSCC autophagy is a critical cellular process in response to IR, it has been poorly explored, needing further studies in order to provide a new strategy to treat HNSCC radioresistance.

10. Metabolic Therapy for HNSCC

Tumour metabolism has been considered as a potential therapeutic target. Both normal proliferating cells and cancer cells, through the Warburg effect, can metabolize nutrients and produce ATP less efficiently than by OXPHOS, regardless of the presence of oxygen. Since cancer cells have an increased proliferative rate, they increase glucose intake to compensate their energy needs [27]. It has been demonstrated that if the Warburg effect is blocked, the death of cancer cells is selectively promoted [49]. Now it is known that most types of cancer contain metabolically functional mitochondria, which have critical function in tumorigenesis [111–113].

There are clear differences between HPV-positive and HPV-negative HNSCC. Moreover, it has been shown that HPV-positive HNSCC has a better prognosis, associated with a better response to radiation treatment, with a 5-year survival rate of 80%, in comparison with the 50% survival rate of HPV-negative HNSCC [3,114]. This contrast has allowed recognizing HPV-positive and HPV-negative HNSCC as two distinct varieties. Despite this, both HNSCC are treated similarly, consisting mainly in surgery with concomitant radio and/or chemotherapy [115,116]. The scope of these standard strategies is limited, since more than 50% of the patients present recurrence, which is associated with the inherent resistance to treatment of HNSCC [117]. The toxicity due to the treatment represents an important issue, so research has focused on new therapeutic strategies to improve outcomes, especially in HPV-negative patients, as well as on a decrease in the intensity of standard therapy for HPV-positive patients.

HPV screening in HNSCC will help to choose a more appropriate therapy according to the characteristics of the tumour, trying to avoid resistance to treatment. For example, oxygen therapy where haemoglobin is increased [118], could be more efficient in HPV-positive HNSCC because these cancers induce ROS in different ways, which could synergize with ROS induced by oxygen and radiation therapy. The use of anti-cancer drugs directed to mitochondria (mitocans) is another possibility to treat HPV-positive HNC. For instance, metformin/phenformin, which besides decreasing blood glucose, insulin levels and PI3K activation, also inhibits complex I of ETC and intermediates of TCA in cancer cells [119,120]. Moreover, the VLX600 drug is an ETC inhibitor, which induces a significant reduction of colon cancer tumour growth [121]. It has also been shown that the use of non-selective beta-blockers such as propranolol displays significant anti-cancer effects in a murine model of recurrent/metastatic HPV-positive HNSCC. VLX600 shows a significant reduction in tumour cell mitochondrial metabolism, which together with dichloroacetate (DCA), a clinically available glycolytic inhibitor, has proved to be an effective therapy against HNSCC in murine models, since the VLX600–DCA combination dramatically attenuates tumour cell metabolism and mTOR signaling [122,123]. This novel combination enhances the effects of standard treatments [124].

On the other hand, since HPV-negative HNSCC increase the glycolytic pathway, anti-glycolytic drugs administered concomitantly to chemotherapy could increase the efficacy in the antitumoral response. For example, tyrosine kinase (TK) inhibitors, such as imatinib, decrease glycolysis, affecting glycolytic enzymes such as HK and PFK-1 via HIF-1 [125]. Moreover, inhibition of fatty acid synthesis,
by blocking fatty acid synthase with different drugs, such as orlistat [77], could be another way to improve treatment response in HPV-negative HNSCC.

Metabolic therapies could have a significant importance in the elimination of cancer cells, since they target the metabolites used to produce energy and cell biomass. Since cancer cells express a particular set of enzymes, these enzymes could be targeted in order to specifically eliminate cancer cells, minimizing injury in normal cells. Therefore, several preclinical and/or clinical studies are being carried out using different compounds that act on metabolic pathways. Such is the case of metformin, which inhibits mitochondrial complex I and the synthesis of lipids and proteins. Metformin, which has been used to treat type II diabetes for over 50 years, has the property of slowing down cancer growth [126,127]. Essentially, since the growth of cancer cells is accelerated in low oxygen concentrations, metformin improves oxygen concentration in cancer tissue, inducing OS and cancer cell death via apoptosis [128]. In this direction, a clinical study that is now being carried out, intends to verify the effect of this drug in the oxygen content in HNC, and to evaluate whether changes in the oxygen content within the tumour can be visualized by means of magnetic resonance imaging (clinicaltrials.gov no NCT03510390).

Preclinical studies showed that lonidamine targets glycolysis through the inhibition of HEKII [129], which increases the expression of the apoptosis-associated proteins Poly (ADP-ribose) polymerase (PARP) and caspase 3, inducing radiosensitization [130,131]. It has been shown that, at concentrations that are safe for humans, lonidamine impedes energy-dependent repair of potentially lethal damage induced by radiation [132]. Previous studies demonstrated that the combination of hyperfractionated radiotherapy and lonidamine increased the proportion of long-term disease-free patients [133].

Dichloroacetate, which inhibits the production and transport of lactate, has been tested for metabolic therapy. A combination of this drug with cisplatin and radiation is already running in a HNSCC clinical trial stage III-IV (NCT01386632). Targeting energetic metabolism as an anti-cancer therapy is a promise for HNSCC treatment. Nevertheless, differences between HPV-positive and -negative HNSCCs cases should be taken into account, in order to use the correct metabolic treatment to obtain the best response.

11. Conclusions

Reprogramming of energy metabolism is an important hallmark in cancer development, which permits cancer cells to continue growing, even under stress conditions such as hypoxia, where nutrients and oxygen are deprived. This hallmark can provide protection to IR in cancer cells. It has been shown that HPV-negative HNSCC tumours induce the reprogramming of energy metabolism, activating the Warburg effect and lipid metabolism in comparison with HPV-positive HNSCC, which favours OXPHOS to obtain ATP. Such metabolic difference in HPV-negative HNSCC coupled with the status of p53, a better capacity of DNA repair and better coping with OS, induce an undesirable response to IR, avoiding cell death and promoting radioresistance, in comparison with HPV-positive HNSCC. However, a small percentage (20%) of HPV-positive HNSCC does not respond properly to treatment, which suggests the necessity of new strategies to cope with this issue. The design of an appropriate therapy to target glycolysis, lipid metabolism or mitochondrial metabolism, associated to HPV status, could improve the response to treatment in HNSCC.

Author Contributions: A.C.-G., M.L., I.M.-R., wrote the paper; A.C.-G. performed the figures; A.C.-G., M.L., I.M.-R., and J.P.-C. contributed in the revision of the manuscript.

Funding: This research received no external funding.

Acknowledgments: This study was partially supported by CONACyT-FOSISS grant 261499 and Instituto Nacional de Cancerologí a, México Ref: (015/039/IBI) (CEI/998/15).

Conflicts of Interest: The authors declare no conflicts of interest.
References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]

2. Chaturvedi, A.K.; Engels, E.A.; Pfeiffer, R.M.; Hernandez, B.Y.; Xiao, W.; Kim, E.; Jiang, B.; Goodman, M.T.; Sibug-Saber, M.; Cozen, W.; et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29, 4294–4301. [CrossRef] [PubMed]

3. Mirghani, H.; Amen, F.; Tao, Y.; Deutsch, E.; Levy, A. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treat. Rev. 2015, 41, 844–852. [CrossRef] [PubMed]

4. Spence, T.; Bruce, J.; Yip, K.W.; Liu, F.-F. HPV Associated Head and Neck Cancer. Cancers 2016, 8, 75. [CrossRef] [PubMed]

5. Ghittoni, R.; Accardi, R.; Hasan, U.; Gheit, T.; Sylla, B.; Tommasino, M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40, 1–13. [CrossRef] [PubMed]

6. Pinatti, L.M.; Walline, H.M.; Carey, T.E. Human Papillomavirus Genome Integration and Head and Neck Cancer. J. Dent. Res. 2015, 94, 844–852. [CrossRef]

7. Thorland, E.C.; Myers, S.L.; Persing, D.H.; Sarkar, G.; McGovern, R.M.; Gostout, B.S.; Smith, D.I. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res. 2000, 60, 5916–5921. [PubMed]

8. Winder, D.M.; Pett, M.R.; Foster, N.; Shivji, M.K.K.; Herdman, M.T.; Venkitaraman, A.R.; Coleman, N. An increase in DNA double-strand breaks, induced by Ku70 depletion, is associated with human papillomavirus 16 episome loss and de novo viral integration events. J. Pathol. 2007, 213, 27–34. [CrossRef]

9. Jang, M.K.; Shen, K.; McBride, A.A. Papillomavirus genomes associate with BRD4 to replicate at fragile sites in the host genome. PLoS Pathog. 2014, 10, e1004117. [CrossRef]

10. Chen Wongworawat, Y.; Filippova, M.; Williams, V.M.; Filippov, V.; Duerksen-Hughes, P.J. Chronic oxidative stress increases the integration frequency of foreign DNA and human papillomavirus 16 in human keratinocytes. Am. J. Cancer Res. 2016, 6, 764–780. [PubMed]

11. Bernier, J.; Hall, E.J.; Giaccia, A. Radiation oncology: A century of achievements. Nat. Rev. Cancer 2004, 4, 737–747. [CrossRef] [PubMed]

12. Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.-W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012, 9, 193–199. [CrossRef] [PubMed]

13. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1–40. [CrossRef]

14. Nijkamp, M.M.; Span, P.N.; Bussink, J.; Kaanders, J.H.A.M. Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2013, 108, 17–23. [CrossRef] [PubMed]

15. Gogineni, V.R.; Nalla, A.K.; Gupta, R.; Dinh, D.H.; Klopfenstein, J.D.; Rao, J.S. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011, 313, 64–75. [CrossRef] [PubMed]

16. Alsoubhi, N.; Middleton, F.; Abdel-Fatah, T.M.A.; Stephens, P.; Doherty, R.; Arora, A.; Moseley, P.M.; Chan, S.Y.T.; Aleskandarany, M.A.; Green, A.R.; et al. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Mol. Oncol. 2016, 10, 213–223. [CrossRef] [PubMed]

17. De Sousa, M.M.L.; Bjørås, K.O.; Hanssen-Bauer, A.; Solvang-Garten, K.; Otterlei, M. p38 MAPK signaling and phosphorylations in the BRCT1 domain regulate XRCC1 recruitment to sites of DNA damage. Sci. Rep. 2017, 7, 6322. [CrossRef]

18. Jang, J.; Huh, Y.J.; Cho, H.-J.; Lee, B.; Park, J.; Hwang, D.-Y.; Kim, D.-W. SIRT1 Enhances the Survival of Human Embryonic Stem Cells by Promoting DNA Repair. Stem Cell Rep. 2017, 9, 629–641. [CrossRef]

19. Xie, Y.; Zhang, J.; Ye, S.; He, M.; Ren, R.; Yuan, D.; Shao, C. SirT1 regulates radiosensitivity of hepatoma cells differently under normoxic and hypoxic conditions. Cancer Sci. 2012, 103, 1238–1244. [CrossRef]
20. Wei, F.; Tang, L.; He, Y.; Wu, Y.; Shi, L.; Xiong, F.; Gong, Z.; Guo, C.; Li, X.; Liao, Q.; et al. BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTn expression. *Cell Death Dis.* 2018, 9, 432. [CrossRef]  
21. Scanlon, C.S.; Van Tubergen, E.A.; Inglehart, R.C.; D’Silva, N.J. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. *J. Dent. Res.* 2013, 92, 114–121. [CrossRef] [PubMed]  
22. Liu, L.-K.; Jiang, X.-Y.; Zhou, X.-X.; Wang, D.-M.; Song, X.-L.; Jiang, H.-B. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: Correlation with the clinicopathological features and patient outcome. *Mod. Pathol.* 2010, 23, 213–224. [CrossRef] [PubMed]  
23. Jerhammar, F.; Ceder, R.; Garvin, S.; Grénav, S.; Graafström, R.C.; Roberg, K. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. *Cancer Biol. Ther.* 2010, 10, 1244–1251. [CrossRef] [PubMed]  
24. Barker, H.E.; Paget, J.T.E.; Khan, A.A.; Harrington, K.J. The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. *Nat. Rev. Cancer* 2015, 15, 409–425. [CrossRef] [PubMed]  
25. Verrecchia, F.; Mauviel, A. Transforming growth factor-beta and fibrosis. *World J. Gastroenterol.* 2007, 13, 3056–3062. [CrossRef] [PubMed]  
26. Brieger, J.; Kattwinkel, J.; Berres, M.; Gosepath, J.; Mann, W.J. Impact of vascular endothelial growth factor release on radiation resistance. *Oncol. Rep.* 2007, 18, 1597–1601. [CrossRef]  
27. Warburg, O. On the origin of cancer cells. *Science* 1956, 123, 309–314. [CrossRef]  
28. Dok, R.; Nuyts, S. HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. *Cancers* 2016, 8, 41. [CrossRef]  
29. Jou, A.; Hess, J. Epidemiology and Molecular Biology of Head and Neck Cancer. *Oncol. Res. Treat.* 2017, 40, 328–332. [CrossRef]  
30. Solomon, B.; Young, R.J.; Rischin, D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. *Semin. Cancer Biol.* 2018, 52, 228–240. [CrossRef]  
31. Stransky, N.; Egloff, A.M.; Tward, A.D.; Kostic, A.D.; Cibulskis, K.; Sivachenko, A.; Kryukov, G.V.; Lawrence, M.S.; Sougnez, C.; McKenna, A.; et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. *Science* 2011, 333, 1157–1160. [CrossRef] [PubMed]  
32. Agrawal, N.; Frederick, M.J.; Pickering, C.R.; Bettegowda, C.; Chang, K.; Li, R.J.; Fakhry, C.; Xie, T.-X.; Zhang, J.; Wang, J.; et al. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. *Clin. Cancer Res.* 2015, 21, 632–641. [CrossRef] [PubMed]  
33. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015, 517, 576–582. [CrossRef] [PubMed]  
34. Seiwert, T.Y.; Zuo, Z.; Keck, M.K.; Khattri, A.; Pedamallu, C.S.; Stricker, T.; Brown, C.; Pugh, T.J.; Stojanov, P.; Cho, J.; et al. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. *Clin. Cancer Res.* 2015, 21, 632–641. [CrossRef] [PubMed]  
35. Mauro, C.; Leow, S.C.; Anso, E.; Rocha, S.; Thotakura, A.K.; Tornatore, L.; Moretti, M.; De Smaele, E.; Beg, A.A.; Tergaonkar, V.; et al. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. *Nat. Cell Biol.* 2011, 13, 1272–1279. [CrossRef] [PubMed]  
36. Kawai, I.; Matsumura, H.; Fujii, W.; Naito, K.; Kusakabe, K.; Kiso, Y.; Kano, K. Discoidin domain receptor 2 (DDR2) regulates body size and fat metabolism in mice. *Transgenic Res.* 2014, 23, 165–175. [CrossRef] [PubMed]  
37. Hao, Y.; Samuels, Y.; Li, Q.; Krokowski, D.; Guan, B.-J.; Wang, C.; Jin, Z.; Dong, B.; Cao, B.; Feng, X.; et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. *Nat. Commun.* 2016, 7, 11971. [CrossRef]  
38. Puzzio-Kuter, A.M. The Role of p53 in Metabolic Regulation. *Genes Cancer* 2011, 2, 385–391. [CrossRef]  
39. Hashibe, M.; Boffetta, P.; Zaridze, D.; Shangina, O.; Szczesnia-Dabrowska, N.; Mates, D.; Janout, V.; Fabianová, E.; Bencko, V.; Moullan, N.; et al. Evidence for an important role of alcohol- and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. *Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cospnsored Am. Soc. Prev. Oncol.* 2006, 15, 696–703. [CrossRef]  
40. D’Souza, G.; Dempsey, A. The role of HPV in head and neck cancer and review of the HPV vaccine. *Prev. Med.* 2011, 53 (Suppl. 1), S5–S11. [CrossRef]  
41. Mallen-St Clair, J.; Alani, M.; Wang, M.B.; Srivatsan, E.S. Human papillomavirus in oropharyngeal cancer: The changing face of a disease. *Biochim. Biophys. Acta* 2016, 1866, 141–150. [CrossRef] [PubMed]
Cancers 2019, 11, 182

42. Kimple, R.J.; Smith, M.A.; Blitzer, G.C.; Torres, A.D.; Martin, J.A.; Yang, R.Z.; Peet, C.R.; Lorenz, L.D.; Nickel, K.P.; Klingelhoitz, A.J.; et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013, 73, 4791–4800. [CrossRef] [PubMed]

43. Rieckmann, T.; Tribius, S.; Grob, T.J.; Meyer, F.; Busch, C.-J.; Petersen, C.; Dikomey, E.; Kriegs, M. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2013, 107, 242–246. [CrossRef] [PubMed]

44. Cruz-Gregorio, A.; Manzo-Merino, J.; González-Garcia, M.C.; Pedraza-Chaverri, J.; Medina-Campos, O.N.; Valverde, M.; Rojas, E.; Rodriguez-Sastre, M.A.; García-Cuellar, C.M.; Lizano, M. Human Papillomavirus Types 16 and 18 Early-expressed Proteins Differentially Modulate the Cellular Redox State and DNA Damage. Int. J. Biol. Sci. 2018, 14, 21–35. [CrossRef] [PubMed]

45. Williams, V.M.; Filippova, M.; Filippov, V.; Payne, K.J.; Duerksen-Hughes, P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J. Virol. 2014, 88, 6751–6761. [CrossRef] [PubMed]

46. Marullo, R.; Werner, E.; Zhang, H.; Chen, G.Z.; Shin, D.M.; Doetsch, P.W. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis 2015, 36, 1397–1406. [CrossRef] [PubMed]

47. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 2010, 48, 749–762. [CrossRef]

48. Holmström, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 2014, 15, 411–421. [CrossRef]

49. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033. [CrossRef]

50. Chen, X.; Mims, J.; Huang, X.; Singh, N.; Motea, E.; Planchon, S.M.; Beg, M.; Tsang, A.W.; Porosnicu, M.; Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033. [CrossRef]

51. Halliwell, B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006, 141, 312–322. [CrossRef] [PubMed]

52. Birben, E.; Sahiner, U.M.; Sackesen, C.; Erzurum, S.; Kalayci, O. Oxidative stress and antioxidant defense. World Allergy Organ. J. 2012, 5, 9–19. [CrossRef] [PubMed]

53. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44–84. [CrossRef] [PubMed]

54. Dhakshinamoorthy, S.; Long, D.J.; Jaiswal, A.K. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr. Top. Cell. Regul. 2000, 36, 201–216. [PubMed]

55. Davies, K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50, 279–289. [CrossRef] [PubMed]

56. Kaspar, J.W.; Niture, S.K.; Jaiswal, A.K. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Antioxid. Redox Signal. 2000, 2, 1397–1406. [CrossRef]

57. Suzuki, T.; Yamamoto, M. Molecular basis of the Keap1-Nrf2 system. Antioxid. Redox Signal. 2000, 2, 1397–1406. [CrossRef]

58. Nickel, K.P.; Klingelhoitz, A.J.; et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013, 73, 4791–4800. [CrossRef] [PubMed]

59. Ewing, P.; Wilke, A.; Eissner, G.; Holler, E.; Andreeßen, R.; Gerbitz, A. Expression of heme oxygenase-1 protects endothelial cells from irradiation-induced apoptosis. Endothel. J. Endothel. Cell Res. 2005, 12, 113–119. [CrossRef]

60. Yokoyama, S.; Mita, S.; Okabe, A.; Abe, M.; Ogawa, M. Prediction of radiosensitivity in human esophageal squamous cell carcinomas with heme oxygenase-1: A clinicopathological and immunohistochemical study. Oncol. Rep. 2001, 8, 355–358. [CrossRef]

61. Lee, S.; Lim, M.-J.; Kim, M.-H.; Yu, C.-H.; Yun, Y.-S.; Ahn, J.; Song, J.-Y. An effective strategy for increasing the radiosensitivity of Human Lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic. Biol. Med. 2012, 53, 807–816. [CrossRef] [PubMed]
62. Chen, M.-F.; Keng, P.C.; Shau, H.; Wu, C.-T.; Hu, Y.-C.; Liao, S.-K.; Chen, W.-C. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. *Int. J. Radiat. Oncol. Biol. Phys.* 2006, 64, 581–591. [CrossRef] [PubMed]

63. Guo, Q.; Huang, X.; Zhang, J.; Luo, Y.; Peng, Z.; Li, S. Downregulation of peroxiredoxin I by a novel fully human phage display recombinant antibody induces apoptosis and enhances radiation sensitization in A549 lung carcinoma cells. *Cancer Biother. Radiopharm.* 2012, 27, 307–316. [CrossRef] [PubMed]

64. Zhang, P.; Singh, A.; Vengasubramanian, S.; Esopi, D.; Kombaira, J.; Bodas, M.; Wu, H.; Bova, S.G.; Biswal, S. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. *Mol. Cancer Ther.* 2010, 9, 336–346. [CrossRef] [PubMed]

65. Lister, A.; Nedjadi, T.; Kitteringham, N.R.; Campbell, F.; Costello, E.; Lloyd, B.; Copple, I.M.; Williams, S.; Owen, A.; Neoptolemos, J.P.; et al. Nrf2 is overexpressed in pancreatic cancer: Implications for cell proliferation and therapy. *Mol. Cancer* 2011, 10, 37. [CrossRef] [PubMed]

66. Namani, A.; Matiur Rahaman, M.; Chen, M.; Tang, X. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer. *BMC Cancer* 2018, 18, 46. [CrossRef] [PubMed]

67. Wang, T.; Hu, P.; Li, B.; Zhang, J.-P.; Cheng, Y.-F.; Liang, Y.-M. Role of Nrf2 signaling pathway in the radiation tolerance of patients with head and neck squamous cell carcinoma: An in vivo and in vitro study. *OncoTargets Ther.* 2017, 10, 1809–1819. [CrossRef]

68. Barger, J.F.; Plas, D.R. Balancing biosynthesis and bioenergetics: Metabolic programs in oncogenesis. *Endocr. Relat. Cancer* 2010, 17, R287–R304. [CrossRef]

69. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 664–674. [CrossRef]

70. Mathupala, S.P.; Ko, Y.H.; Pedersen, P.L. Hexokinase II: Cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. *Oncogene* 2006, 25, 4777–4786. [CrossRef]

71. Van Veelen, C.W.; Rijken, G.; Van Ketel, B.A.; Staal, G.E. The pyruvate kinase isoenzyme shift in human gliomas: A potential marker in the treatment of gliomas. *Br. J. Neurosurg.* 1988, 2, 257–263. [CrossRef] [PubMed]

72. Dominguez, J.E.; Graham, J.F.; Cummins, C.J.; Loreck, D.J.; Galarraga, J.; Van der Feen, J.; DeLaPaz, R.; Smith, B.H. Enzymes of glucose metabolism in cultured human gliomas: Neoplasia is accompanied by altered hexokinase, phosphofructokinase, and glucose-6-phosphate dehydrogenase levels. *Metab. Brain Dis.* 1997, 2, 17–30. [CrossRef] [PubMed]

73. Dang, C.V.; Semenza, G.L. Oncogenic alterations of metabolism. *Trends Biochem. Sci.* 1999, 24, 68–72. [CrossRef]

74. Flier, J.S.; Mueckler, M.M.; Usher, P.; Lodish, H.F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. *Science* 1987, 235, 1492–1495. [CrossRef]

75. Kunkel, M.; Moergel, M.; Stockinger, M.; Jeong, J.-H.; Fritz, G.; Lehr, H.-A.; Whiteside, T.L. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. *Oral Oncol.* 2007, 43, 796–803. [CrossRef]

76. Yan, S.-X.; Luo, X.-M.; Zhou, S.-H.; Bao, Y.-Y.; Fan, J.; Lu, Z.-J.; Liao, X.-B.; Huang, Y.-P.; Wu, T.-T.; Wang, Q.-Y. Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. *Int. J. Mol. Sci.* 2013, 14, 1375–1386. [CrossRef] [PubMed]

77. Mims, J.; Bansal, N.; Bharadwaj, M.S.; Chen, X.; Molina, A.J.; Tsang, A.W.; Furdui, C.M. Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer. *Radiat. Res.* 2015, 183, 291–304. [CrossRef]

78. Jung, Y.-S.; Najy, A.J.; Huang, W.; Sethi, S.; Snyder, M.; Sakr, W.; Dyson, G.; Hüttemann, M.; Lee, I.; Ali-Fehmi, R.; et al. HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer. *OncoT argets Ther.* 2017, 10, 235, 1492–1495. [CrossRef] [PubMed]

79. Vyas, S.; Zaganjor, E.; Haigis, M.C. Mitochondria and Cancer. *Cell* 2016, 166, 555–566. [CrossRef]

80. Kam, W.W.-Y.; Banati, R.B. Effects of ionizing radiation on mitochondria. *Free Radic. Biol. Med.* 2013, 65, 607–619. [CrossRef]

81. Li, Y.; Chang, J.T.; Lee, L.-Y.; Fan, K.-H.; Lu, Y.-C.; Li, Y.-C.; Chiang, C.-H.; You, G.-R.; Chen, H.-Y.; Cheng, A.-J. GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating
cellular reactive oxygen species via a SMAD-associated signaling pathway. Oncotarget 2017, 8, 1508–1528. [CrossRef] [PubMed]

82. Holley, A.K.; Miao, L.; St Clair, D.K.; St Clair, W.H. Redox-modulated phenomena and radiation therapy: The central role of superoxide dismutases. Antioxid. Redox Signal. 2014, 20, 1567–1589. [CrossRef] [PubMed]

83. Qu, Y.; Zhang, H.; Zhao, S.; Hong, J.; Tang, C. The effect on radioresistance of manganese superoxide dismutase in nasopharyngeal carcinoma. Oncol. Rep. 2010, 23, 1005–1011. [PubMed]

84. Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 1997, 3, 614–620. [CrossRef] [PubMed]

85. Aebersold, D.M.; Kollar, A.; Beer, K.T.; Laissie, J.; Greiner, R.H.; Djonov, V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int. J. Cancer 2001, 96, 41–54. [CrossRef]

86. Kuwahara, Y.; Oikawa, T.; Ochiai, Y.; Roudkenar, M.H.; Fukumoto, M.; Shimura, T.; Ohtake, Y.; Ohkubo, Y.; Mori, S.; Uchiyama, Y.; et al. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011, 2, e177. [CrossRef] [PubMed]

87. Condon, L.T.; Ashman, J.N.E.; Ell, S.R.; Stafford, N.D.; Greenman, J.; Cawkwell, L. Overexpression of Bcl-2 and its role in regulating apoptosis. FEBS J. 2012, 279, 592S–599S. [CrossRef] [PubMed]

88. Santos, C.R.; Schulze, A. Lipid metabolism in cancer. J. Nutr. 2012, 142, 592S–599S. [CrossRef] [PubMed]

89. Calder, P.C. Mechanisms of action of (n-3) fatty acids. J. Nutr. 2002, 132, 793–945. [CrossRef] [PubMed]

90. Santos, C.R.; Schulze, A. Lipid metabolism in cancer. FEBS J. 2012, 279, 2610–2623. [CrossRef]

91. Larsson, S.C.; Kumlin, M.; Ingelman-Sundberg, M.; Wolk, A. Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am. J. Clin. Nutr. 2004, 79, 935–945. [CrossRef] [PubMed]

92. Holley, A.K.; Miao, L.; St Clair, D.K.; St Clair, W.H. Redox-modulated phenomena and radiation therapy: The central role of superoxide dismutases. Antioxid. Redox Signal. 2014, 20, 1567–1589. [CrossRef] [PubMed]

93. Kim, J.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185. [CrossRef] [PubMed]

94. Weljie, A.M.; Jirik, F.R. Hypoxia-induced metabolic shifts in cancer cells: Moving beyond the Warburg effect. Int. J. Biochem. Cell Biol. 2011, 43, 981–989. [CrossRef] [PubMed]

95. Beloribi-Djefaflia, S.; Vasseur, S.; Guillaumond, F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016, 5, e189. [CrossRef] [PubMed]

96. Calder, P.C. Mechanisms of action of (n-3) fatty acids. J. Nutr. 2012, 142, 592S–599S. [CrossRef] [PubMed]

97. Larsson, S.C.; Kumlin, M.; Ingelman-Sundberg, M.; Wolk, A. Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am. J. Clin. Nutr. 2004, 79, 935–945. [CrossRef] [PubMed]

98. Santos, C.R.; Schulze, A. Lipid metabolism in cancer. FEBS J. 2012, 279, 2610–2623. [CrossRef]

99. Bozza, P.T.; Viola, J.P.B. Lipid droplets in inflammation and cancer. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82, 243–250. [CrossRef]

100. Corre, I.; Niaudet, C.; Paris, F. Plasma membrane signaling induced by ionizing radiation. Mutat. Res. 2010, 704, 61–67. [CrossRef]

101. Ackerman, D.; Simon, M.C. Hypoxia, lipids, and cancer: Surviving the harsh tumor microenvironment. Trends Cell Biol. 2014, 24, 472–478. [CrossRef] [PubMed]

102. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell 2008, 132, 27–42. [CrossRef] [PubMed]

103. White, E. The role for autophagy in cancer. J. Clin. Investig. 2015, 125, 42–46. [CrossRef] [PubMed]

104. Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 2017, 17, 528–542. [CrossRef] [PubMed]

105. Kimmelman, A.C.; White, E. Autophagy and Tumor Metabolism. Cell Metab. 2017, 25, 1037–1043. [CrossRef] [PubMed]

106. Kuwahara, Y.; Oikawa, T.; Ochiai, Y.; Roudkenar, M.H.; Fukumoto, M.; Shimura, T.; Ohtake, Y.; Ohkubo, Y.; Mori, S.; Uchiyama, Y.; et al. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011, 2, e177. [CrossRef] [PubMed]
107. Huang, Y.; Guerrero-Preston, R.; Ratovitski, E.A. Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle Georget. Tex 2012, 11, 1247–1259. [CrossRef] [PubMed]

108. Mørgel, M.; Abt, E.; Stockinger, M.; Kunkel, M. Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol. 2010, 46, 667–671. [CrossRef]

109. Zhou, X.; Münger, K. Expression of the human papillomavirus type 16 E7 oncoprotein induces an autophagy-related process and sensitizes normal human keratinocytes to cell death in response to growth factor deprivation. Virology 2009, 385, 192–197. [CrossRef]

110. Spangle, J.M.; Münger, K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J. Virol. 2010, 84, 9398–9407. [CrossRef]

111. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9, 447–464. [CrossRef] [PubMed]

112. Porporato, P.E.; Filigheddu, N.; Pedro, J.M.B.-S.; Kroemer, G.; Galluzzi, L. Mitochondrial metabolism and cancer. Cell Res. 2018, 28, 265–280. [CrossRef] [PubMed]

113. Weinberg, S.E.; Chandel, N.S. Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 2015, 11, 9–15. [CrossRef] [PubMed]

114. Ragin, C.C.R.; Modugno, F.; Gollin, S.M. The epidemiology and risk factors of head and neck cancer: A focus on human papillomavirus. J. Dent. Res. 2007, 86, 104–114. [CrossRef] [PubMed]

115. Perri, F.; Pacelli, R.; Della Vittoria Scarpati, G.; Cella, L.; Giuliani, M.; Caponigro, F.; Pepe, S. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head Neck 2015, 37, 763–770. [CrossRef] [PubMed]

116. Dimery, I.W.; Hong, W.K. Overview of combined modality therapies for head and neck cancer. J. Natl. Cancer Inst. 1993, 85, 95–111. [CrossRef] [PubMed]

117. Genden, E.M.; Ferlito, A.; Bradley, P.J.; Rinaldo, A.; Scully, C. Neck disease and distant metastases. Oral Oncol. 2003, 39, 207–212. [CrossRef]

118. Hoff, C.M. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol. Stockh. Swed. 2012, 51, 419–432. [CrossRef]

119. Wheaton, W.W.; Weinberg, S.E.; Hamanaka, R.B.; Soberanes, S.; Sullivan, L.B.; Anso, E.; Glasauer, A.; Dufour, E.; Mutlu, G.M.; Budigner, G.S.; et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 2014, 3, e02242. [CrossRef]

120. Janzer, A.; German, N.J.; Gonzalez-Herrera, K.N.; Asara, J.M.; Haigis, M.C.; Struhl, K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc. Natl. Acad. Sci. USA 2014, 111, 10574–10579. [CrossRef]

121. Zhang, X.; Fryknäs, M.; Hernlund, E.; Fayad, W.; De Miltio, A.; Olofsson, M.H.; Gogvadze, V.; Dang, L.; Pålhlman, S.; Schughart, L.A.K.; et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun. 2014, 5, 3295. [CrossRef] [PubMed]

122. Lucido, C.T.; Callejas-Valera, J.L.; Colbert, P.L.; Vermeer, D.W.; Miskimins, W.K.; Spanos, W.C.; Vermeer, P.D. β2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC. Oncogenesis 2018, 7, 81. [CrossRef] [PubMed]

123. Lucido, C.T.; Miskimins, W.K.; Vermeer, P.D. Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC. Cancers 2018, 10, 476. [CrossRef] [PubMed]

124. Kluza, J.; Jendoubi, M.; Ballot, C.; Dammak, A.; Jonneaux, A.; Idziorek, T.; Joha, S.; Dauphin, V.; Malet-Martino, M.; Balayssac, S.; et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemia cells. PLoS ONE 2011, 6, e21924. [CrossRef]

125. Zhao, F.; Mancuso, A.; Bui, T.V.; Tong, X.; Gruber, J.J.; Swider, C.R.; Sanchez, P.V.; Lum, J.J.; Sayed, N.; Melo, J.V.; et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprogramming. Oncogene 2010, 29, 2962–2972. [CrossRef]

126. Sharma, P.; Kumar, S. Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: Pivotal role of superoxide dismutase (SOD). Cell. Oncol. Dordr. 2018, 41, 637–650. [CrossRef] [PubMed]
127. Li, Y.; Wang, M.; Zhi, P.; You, J.; Gao, J.-Q. Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models. *Oncotarget* 2018, 9, 2158–2174. [CrossRef]

128. Zannella, V.E.; Pra, A.D.; Muaddi, H.; McKee, T.D.; Stapleton, S.; Sykes, J.; Glicksman, R.; Chaib, S.; Zamiara, P.; Milosevic, M.; et al. Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. *Clin. Cancer Res.* 2013. [CrossRef]

129. Floridi, A.; Paggi, M.G.; Marcante, M.L.; Silvestrini, B.; Caputo, A.; De Martino, C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. *J. Natl. Cancer Inst.* 1981, 66, 497–499.

130. Liu, Y.; Murray-Stewart, T.; Casero, R.A.; Kagiampakis, I.; Jin, L.; Zhang, J.; Wang, H.; Che, Q.; Tong, H.; Ke, J.; et al. Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth. *Int. J. Oncol.* 2017, 50, 2011–2023. [CrossRef]

131. Nath, K.; Guo, L.; Nancolas, B.; Nelson, D.S.; Shestov, A.A.; Lee, S.-C.; Roman, J.; Zhou, R.; Leeper, D.B.; Halestrap, A.P.; et al. Mechanism of antineoplastic activity of lonidamine. *Biochim. Biophys. Acta* 2016, 1866, 151–162. [CrossRef] [PubMed]

132. Hahn, G.M.; van Kersen, I.; Silvestrini, B. Inhibition of the recovery from potentially lethal damage by lonidamine. *Br. J. Cancer* 1994, 50, 657–660. [CrossRef] [PubMed]

133. Magni, L.; Terraneo, F.; Bertoni, F.; Tordiglione, M.; Bardelli, D.; Rosignoli, M.T.; Ciottoli, G.B. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 1994, 29, 45–55. [CrossRef]